Ganitumab - Amgen

Drug Profile

Ganitumab - Amgen

Alternative Names: AMG-479

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Millennium; NantWorks; National Cancer Institute (USA); Novartis; Takeda; Takeda Oncology; UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ewing's sarcoma
  • Phase II Solid tumours
  • Phase Unknown Rhabdomyosarcoma
  • No development reported Breast cancer; Colorectal cancer; Sarcoma; Small cell lung cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 May 2018 Novartis terminates a phase I/II trial due to competitive landscape for anticancer therapies in ovarian and breast cancer and given the limited clinical activity observed with combination treatment for Solid tumours (Combination therapy, Late-stage disease) in USA, Belgium, Canada and Spain (IV) (NCT01708161)
  • 01 Jun 2017 NantCell completes a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease) in USA, Belgium, Canada and Spain (IV) (NCT01708161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top